SHP.L - Shire plc

LSE - LSE Delayed price. Currency in GBp
3,677.50
-71.00 (-1.89%)
At close: 5:02PM BST
Stock chart is not supported by your current browser
Previous close3,748.50
Open3,779.50
Bid3,655.00 x 51000
Ask3,990.00 x 53800
Day's range3,666.50 - 3,781.50
52-week range3,603.50 - 5,186.00
Volume2,681,931
Avg. volume2,621,480
Market cap33.17B
Beta1.80
PE ratio (TTM)49.36
EPS (TTM)74.5
Earnings date27 Oct 2017
Forward Dividend & Yield0.26 (0.51%)
Ex-dividend date2016-09-08
1y target est70.16
  • Shire's New Formulation of Oncaspar Gets CHMP Recommendation
    Zacks6 days ago

    Shire's New Formulation of Oncaspar Gets CHMP Recommendation

    Shire's (SHPG) marketing authorization application for a new (dried) formulation of its leukemia drug, Oncaspar, received CHMP recommendation for approval in EU.

  • Activist fund seeks break-up of £35bn pharma group Shire
    Sky News8 days ago

    Activist fund seeks break-up of £35bn pharma group Shire

    A US hedge fund is demanding a string of divestments at the FTSE-100 biotech group Shire (Xetra: S7E.DE - news) , underlining growing interest among activist investors in large European companies. Sky News has learnt that Sachem Head Capital Management is urging the board of Shire, which specialises in treatments for rare diseases and neuroscience products, to explore a sale or spin-off of several of its assets. The move, which has been raised during discussions between the hedge fund and Shire directors in recent months, comes after Sachem Head disclosed during the summer that it had acquired a small stake in the pharmaceuticals group.

  • GlobeNewswire10 days ago

    Shire plc : New Formulation of ONCASPAR® (pegaspargase) Receives Positive CHMP Opinion in Europe for Patients with Acute Lymphoblastic Leukemia (ALL)

    New Formulation of ONCASPAR ® (pegaspargase) Receives Positive CHMP Opinion in Europe for Patients with Acute Lymphoblastic Leukemia (ALL) If approved, lyophilized formulation would offer three times longer ...

  • GlobeNewswire17 days ago

    Shire plc : Director/PDMR Shareholding

    Director/PDMR Shareholding   October 5, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company")   Notification of transactions by person discharging managerial responsibilities   1. Details ...

  • GlobeNewswire19 days ago

    Shire plc : Director/PDMR Shareholding

    Director/PDMR Shareholding   October 3, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG)   Notification of transactions by persons discharging managerial responsibilities   1. Details of the person discharging ...

  • The Wall Street Journal20 days ago

    Shire Alleges Allergan Blocked Drug From Medicare Contracts

    Shire filed an antitrust suit against Allergan, alleging Allergan’s contracts with Medicare Part D drug plans for its Restasis eye drops effectively blocked access to Shire’s rival drug.

  • Reuters20 days ago

    Shire sues Allergan in U.S. over dry eye drug

    In a complaint filed with the federal court in Newark, New Jersey, Shire accused Allergan of violating antitrust laws to preserve its roughly 90 percent share in Medicare prescription drug plans for its older and "clinically inferior" dry eye drug Restasis, and block prescriptions of Shire's rival drug Xiidra. "Quite simply, Allergan has and will continue to use bundled discounts, exclusive dealing, coercion and interference to unlawfully 'block' Shire from competing with it, and to maintain its monopoly in the Part D market at all costs," Shire said, referring to the Medicare drug plans.

  • Reuters - UK Focus20 days ago

    Shire sues Allergan in U.S. over dry eye drug

    Oct (Shenzhen: 000069.SZ - news) 2 (Reuters) - Allergan Plc (Frankfurt: A1W5NE - news) was sued on Monday by Shire Plc (Xetra: S7E.DE - news) for allegedly scheming to block doctors from prescribing its new treatment for dry eye disease. In a complaint filed with the federal court in Newark, New (KOSDAQ: 160550.KQ - news) Jersey, Shire accused Allergan of violating antitrust laws to preserve its roughly 90 percent share in Medicare prescription drug plans for its older and "clinically inferior" dry eye drug Restasis, and block prescriptions of Shire's rival drug Xiidra. "Quite simply, Allergan has and will continue to use bundled discounts, exclusive dealing, coercion and interference to unlawfully 'block' Shire from competing with it, and to maintain its monopoly in the Part D market at all costs," Shire said, referring to the Medicare drug plans.

  • GlobeNewswire20 days ago

    Shire plc : Total voting rights

    Total Voting Rights October 2, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company"), in accordance with 5.6.1R of the Financial Conduct Authority`s (the "FCA") Disclosure Guidance ...

  • Fool.co.uklast month

    This small-cap growth stock could be a millionaire-maker

    Bilaal Mohamed believes this hidden gem could help you on the road to riches.

  • Reuters - UK Focuslast month

    Shire says trial shows new HAE drug significantly reduces attacks

    London-listed drugmaker Shire (Hamburg: 3979575.HM - news) said on Monday it had successfully tested a new medicine that prevents attacks in patients with hereditary angioedema (HAE), a rare genetic disease that causes swelling of extremities, the gastrointestinal tract and upper airways. "We are very pleased with the strong results of this study, which demonstrated efficacy with a low-volume dosing regimen, and what it potentially could mean for the global HAE community, if approved," said Shire (Xetra: S7E.DE - news) 's head of research and development, Howard Mayer.

  • Fool.co.uk2 months ago

    Why I think Indivior plc is a growth stock for shrewd investors

    You shouldn't count out Indivior plc (LSE: INDV) just yet.

  • Reuters - UK Focus2 months ago

    Shire defends record as UBS cuts price target on staff satisfaction reviews

    Shire (Xetra: S7E.DE - news) is weathering a period a major change well, the company said on Tuesday, as analysts at UBS (LSE: 0QNR.L - news) cut their price target on the stock in response to signs of falling staff satisfaction at the drugmaker. A trawl of 20,000 employee reviews from careers website Glassdoor showed a major decline in staff satisfaction at Shire (Hamburg: 3979575.HM - news) in 2017, with the company coming 24th out of 26 biopharmaceutical companies on "overall satisfaction", UBS said. Shire, which recently lost its chief financial officer and head of research, faces testing times after buying United (Shenzhen: 000925.SZ - news) States-based Baxalta (Xetra: 9BX.DE - news) in its biggest ever deal, leading to inevitable upheaval and challenges.

  • Fool.co.uk2 months ago

    2 bargain recovery stocks that could make you brilliantly rich

    These two shares offer wide margins of safety.

  • Fool.co.uk2 months ago

    Why this battered pharma stock could be a top turnaround buy

    Roland Head selects his turnaround pick from two of this year's biggest pharma fallers.

  • Reuters - UK Focus2 months ago

    BUZZ-Shire claws back from 17-month low after CFO exit

    ** Drugmaker Shire recovers some ground following Monday's 4% fall to a 17-month low on news CFO Jeff Poulton is leaving at the end of the year to join Boston-based plant technology start-up Indigo Ag ...

  • Reuters - UK Focus2 months ago

    Shire's CFO resigns to join plant technology start-up

    Pharmaceutical company Shire (Hamburg: 3979575.HM - news) said its chief financial officer Jeff Poulton will stand down at the end of the year to join Indigo Ag, a Boston-based start-up that seeks to improve agricultural productivity. Poulton, who joined Shire (Xetra: S7E.DE - news) in 2003, has been CFO since January 2015, a period that saw Shire make its largest acquisition with the $32 billion purchase of Baxalta (Xetra: 9BX.DE - news) last year.

  • Reuters - UK Focus2 months ago

    Denmark's ISS hit by headwind in Sweden and China, shares down

    Danish facility services company ISS A/S (LSE: 0QRS.L - news) narrowed its 2017 growth forecast to the low end of its earlier range due to weak sales in Sweden and China, sending its shares down. * ISS has lost revenue in China 'on purpose' as it is leaving the low end of the retail marked, Chief Executive Jeff Gravenhorst told Reuters.

  • Reuters - UK Focus3 months ago

    Shire may spin off hyperactivity drugs, raises forecasts

    Shire (Xetra: S7E.DE - news) , the London-listed pharmaceutical firm built up by acquisitions, said it might spin off its hyperactivity drugs business into a separate company and focus solely on rare disease treatments. Chief Executive Flemming Ornskov said the recent approval of its newest ADHD (attention deficit hyperactivity disorder) drug, and strong demand for its blockbuster Vyvanse, meant the business could thrive as a standalone company.

  • Reuters - UK Focus3 months ago

    Shire upgrades earnings guidance after Q2 earnings beat

    London-listed pharmaceutical maker Shire upgraded its forecast for full-year earnings on Thursday as it reported 7 percent growth in second-quarter product sales. The company said it had upgraded the midpoint ...

  • Reuters - UK Focus3 months ago

    Shire, Roche slug it out in billion-dollar haemophilia drug battle

    Swiss drugmaker Roche's bid to take a chunk of the $11 billion haemophilia drug market dominated by Shire took another blow with the Irish company winning a preliminary injunction over its Swiss rival's medication. Shire said its injunction in a court in Germany, where Roche presented data on its drug emicizumab on Monday, sought to remedy Roche's "incomplete and misleading" statements about the role of Shire's drug FEIBA in adverse events in Roche trials.

  • Reuters - UK Focus3 months ago

    Roche, Shire court fight underscores high stakes in haemophilia

    Roche's bid to muscle in on Shire's share of the $11 billion haemophilia drug market took a new, contentious turn this weekend when the British drugmaker won a court injunction against how the Swiss drugmaker talks about its new medicine. Shire's injunction on Sunday in a Hamburg, Germany, court alleges incomplete and misleading statements by Roche about its investigational emicizumab.

  • Reuters - UK Focus3 months ago

    Shire gets injunction against Roche over haemophilia drug

    Pharmaceutical group Shire (Hamburg: 3979575.HM - news) said on Sunday it had obtained a preliminary injunction in a Hamburg court against rival Roche over its haemophilia drug emicizumab, alleging incomplete and misleading statements surrounding the treatment. Swiss drugmaker Roche is hoping to win a slice of the $11 billion-a-year haemophilia drug market with emicizumab, also known as ACE910 and designed to compete with more traditional treatments from Novo Nordisk (LSE: 0QIU.L - news) and Shire (Xetra: S7E.DE - news) .

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes